New Delhi, Dec 14 (PTI) Biotechnology major Biocon on Wednesday said it has initiated a clinical study in collaboration with Equillium Inc to evaluate efficacy of Itolizumab in patients with Ulcerative Colitis.

This is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naive patients with moderate to severely active Ulcerative Colitis (UC), Biocon said in a statement.

Also Read | 5G Rollout: Delhi, Mumbai Among 50 Cities To Have 5G Services, Says MoS for Telecommunications Devusinh Chauhan.

Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialised in handling UC cases, it added.

The first patient who intended to participate in the study was screened on December 1, 2022, the company said.

Also Read | MPPEB Recruitment 2023: Vacancies Notified for 2716 Assistant, Stenographer and Other Posts at peb.mp.gov.in, Check Eligibility, Last Date, and Other Details Here.

"The commencement of the Phase two clinical study, that will determine its efficacy for the treatment of Ulcerative Colitis, is an important step forward in our efforts to bring its benefit to patients in India suffering from this disease," Biocon Managing Director and CEO Siddharth Mittal said.

The development also underpins the company's commitment to bring innovative, affordable medicines, that address unmet patient needs, to market expeditiously, he added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)